Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine

Phase 3

Recruiting

Conditions: Dravet Syndrome (DS)
Lennox-Gastaut Syndrome (LGS)

Interventions: Drug: Soticlestat

First Posted Date: 2024-05-21

Last Posted Date: 2024-05-21

Lead Sponsor: Takeda

Target Recruit Count: 45

Registration Number: NCT06422377

Locations: 🇩🇰
Epilepsihospitalet Filadelfia, Dianalund, Zealand, Denmark

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Phase 3

Not yet recruiting

Conditions: Ulcerative Colitis
Crohn's Disease

Interventions: Drug: Vedolizumab SC
Other: No Intervention

First Posted Date: 2024-05-08

Last Posted Date: 2024-11-25

Lead Sponsor: Takeda

Target Recruit Count: 70

Registration Number: NCT06405087

A Study on Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS) in Children, Teenagers and Adults in Portugal

Withdrawn

Conditions: Lennox-Gastaut Syndrome (LGS)
Dravet Syndrome (DS)

Interventions: Other: No Intervention

First Posted Date: 2024-05-02

Last Posted Date: 2024-10-03

Lead Sponsor: Takeda

Target Recruit Count: 100

Registration Number: NCT06395792

A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors

Phase 1

Recruiting

Conditions: Ovarian Cancer
Solid Tumors

Interventions: Drug: TAK-853

First Posted Date: 2024-04-30

Last Posted Date: 2024-12-06

Lead Sponsor: Takeda

Target Recruit Count: 25

Registration Number: NCT06390995

Locations: 🇯🇵
Keio University Hospital, Shinjuku-ku, Tokyo, Japan
🇯🇵
Chiba University Hospital, Chiba, Japan
🇯🇵
Kyoto University Hospital, Kyoto, Japan

and more 17 locations

A Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Malaysia

Recruiting

Conditions: Dengue Fever

Interventions: Other: No Intervention

First Posted Date: 2024-04-29

Last Posted Date: 2024-10-17

Lead Sponsor: Takeda

Target Recruit Count: 10000

Registration Number: NCT06388785

Locations: 🇲🇾
Universiti Putra Malaysia, Serdang, Selangor, Malaysia
🇲🇾
Universiti Malaya, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN)

Phase 1

Not yet recruiting

Conditions: Refractory Lupus Nephritis

Interventions: Biological: TAK-007
Drug: Chemotherapy Agents

First Posted Date: 2024-04-22

Last Posted Date: 2024-12-03

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT06377228

A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China

Recruiting

Conditions: Hereditary Angioedema (HAE)

Interventions: Other: No intervention

First Posted Date: 2024-04-04

Last Posted Date: 2024-12-13

Lead Sponsor: Takeda

Target Recruit Count: 130

Registration Number: NCT06346899

Locations: 🇨🇳
The Second Affiliated hospital of Xian Jiaotong University, Xian, Shanxi, China
🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujan, China

and more 10 locations

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Phase 3

Recruiting

Conditions: Generalized Pustular Psoriasis
Erythrodermic Psoriasis

Interventions: Drug: TAK-279

First Posted Date: 2024-03-21

Last Posted Date: 2024-12-06

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT06323356

Locations: 🇯🇵
Nagoya City University Hospital, Nagoya, Aichi, Japan
🇯🇵
Fujita Health University Hospital, Toyoake, Aichi, Japan
🇯🇵
Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan

and more 17 locations

A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Repaglinide
Drug: Midazolam
Drug: TAK-279

First Posted Date: 2024-03-04

Last Posted Date: 2024-05-23

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT06290050

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension) in the Body of Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Budesonide

First Posted Date: 2024-02-20

Last Posted Date: 2024-12-02

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT06268301

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy